A Twelve-Week Placebo-Controlled Study of Prazosin in the Treatment of Prostatic Obstruction
| Autor: | E.J.G. Milroy, T. J. Christmas, Christopher R. Chapple |
|---|---|
| Rok vydání: | 1990 |
| Předmět: |
Male
medicine.medical_specialty Time Factors Urethral Obstruction Urology Prostatic Hyperplasia Placebo-controlled study Placebo law.invention Detrusor instability Double-Blind Method Randomized controlled trial law Prazosin medicine Humans Adverse effect Aged Randomized Controlled Trials as Topic Aged 80 and over business.industry Middle Aged Hyperplasia medicine.disease Clinical trial Urodynamics business medicine.drug |
| Zdroj: | Europe PubMed Central |
| ISSN: | 1423-0399 0042-1138 |
| Popis: | Fifty-eight normotensive patients with benign prostatic hyperplasia and maximum urinary flow rates of less than 15 ml/s were randomly assigned to receive a 12-week course of treatment with prazosin or placebo in a double-blind parallel group trial. Prazosin was administered orally in doses of 0.5 mg and then 1 mg twice daily for 4 days each and 2 mg twice daily for the remainder of the trial. Patients on treatment with prazosin had an increased urinary flow rate as compared to placebo with a significant reduction in maximum voiding detrusor pressure and maximum detrusor pressure at peak urinary flow. Although a significant effect on frequency was not demonstrated, standard parameters of detrusor instability were reduced. Investigators' double-blind overall assessment of efficacy significantly favoured the prazosin treatment. Twelve patients were excluded from the final analysis, 8 being withdrawn because of adverse effects, 5 on treatment with prazosin and 3 in the placebo group. Oral prazosin appears to be safe and effective in the long-term treatment of patients with benign prostatic hyperplasia. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|